# The multi-target protective effects of quercetin in cerebrovascular diseases: a dietary strategy for endothelial repair and neuroprotection

**Authors:** Tong Lu, Junjie Gao, Ping Zhu, Ruoxue Cao, Kai Ye

PMC · DOI: 10.3389/fnut.2026.1775964 · Frontiers in Nutrition · 2026-02-18

## TL;DR

Quercetin, a plant compound, shows potential in protecting the brain and blood vessels by targeting multiple pathways, but its use is limited by poor absorption and delivery.

## Contribution

The paper highlights quercetin's multi-target mechanisms in cerebrovascular diseases and proposes nanotechnology-based delivery systems to improve its clinical application.

## Key findings

- Quercetin protects blood vessels by boosting antioxidants and reducing inflammation.
- It supports brain health by preventing cell death and improving neural function.
- Nanotechnology could enhance quercetin's delivery to the brain and increase its effectiveness.

## Abstract

Cerebrovascular diseases, including ischemic stroke and vascular cognitive impairment, represent a significant global health challenge due to the paucity of effective treatment options. Quercetin, a dietary flavonol, has emerged as a promising multi-target neuroprotective compound. This review elucidates the core mechanisms by which quercetin achieves vascular repair and neuroprotection in cerebrovascular diseases through synergistic regulation of multiple signaling pathways and explores strategies to bridge the gap between dietary intake and clinical application. At the vascular level, quercetin enhances antioxidant defense by activating the nuclear factor E2-related factor 2/heme oxygenase-1 axis, inhibits the Toll-like receptor 4/nuclear factor-κB pathway and NOD-like receptor protein 3 inflammasome, and maintains blood–brain barrier integrity by inhibiting matrix metalloproteinase-9 and upregulating tight junction proteins via the Wnt/β-catenin signaling pathway. At the neural level, quercetin inhibits apoptosis through the brain-derived neurotrophic factor-PI3K/Akt pathway, promotes M1-to-M2 microglial polarization to control neuroinflammation, and enhances synaptic plasticity. Additionally, quercetin exerts beneficial effects on mitochondrial protection and calcium homeostasis regulation. However, quercetin currently faces significant barriers to bioavailability, including low oral bioavailability and limited ability to cross the blood–brain barrier. Emerging nanotechnology-based delivery systems, including liposomes, exosomes, and reactive oxygen species-responsive nanoparticles, can enhance brain targeting and bioavailability. Future research should prioritize promoting dietary patterns rich in flavonoid compounds while developing advanced formulations validated through rigorous clinical trials. This approach will help clarify effective dosages, safety profiles, and clinical endpoint benefits across different stages of cerebrovascular disease. In summary, quercetin represents a promising candidate for cerebrovascular disease intervention; however, technological innovations are urgently needed to overcome bioavailability limitations and generate conclusive clinical evidence.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], HMOX1 (heme oxygenase 1) [NCBI Gene 3162], TLR4 (toll like receptor 4) [NCBI Gene 7099], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], BDNF (brain derived neurotrophic factor) [NCBI Gene 627]
- **Chemicals:** quercetin (PubChem CID 5280343)
- **Diseases:** ischemic stroke (MONDO:1060198)

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PVALB (parvalbumin) [NCBI Gene 5816] {aka D22S749}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CALB1 (calbindin 1) [NCBI Gene 793] {aka CALB, D-28K}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, ARG1 (arginase 1) [NCBI Gene 383], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, Tjp1 (tight junction protein 1) [NCBI Gene 292994] {aka ZO-1}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, Cldn5 (claudin 5) [NCBI Gene 65131], TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217] {aka ASK1, MAPKKK5, MEKK5}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Syp (synaptophysin) [NCBI Gene 24804] {aka Syp1}, Wnt2 (Wnt family member 2) [NCBI Gene 114487] {aka Wnt}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}
- **Diseases:** neurodegenerative pathology (MESH:D019636), Inflammation (MESH:D007249), neuroinflammation (MESH:D000090862), Cerebral ischemia (MESH:D002545), Endothelial dysfunction (MESH:D014652), tumor (MESH:D009369), ischemic brain (MESH:D020520), permanent disability (MESH:D003638), Alzheimer's disease (MESH:D000544), neurotoxic (MESH:D020258), acute stroke (MESH:D020521), obesity (MESH:D009765), cerebral edema (MESH:D001929), acute ischemic stroke (MESH:D000083242), neurological deficits (MESH:D009461), Ischemia (MESH:D007511), ischemic or hemorrhagic stroke (MESH:D002543), middle cerebral artery occlusion (MESH:D020244), vascular dementia (MESH:D015140), brain injury (MESH:D001930), reperfusion injury (MESH:D015427), Cerebrovascular diseases (MESH:D002561), cerebral ischemic injury (MESH:D017202), Ischemic stroke (MESH:D002544), cardiovascular disease (MESH:D002318), glutamate excitotoxicity (MESH:C537425), dementia (MESH:D003704), pathology (MESH:D005598), infarct (MESH:D007238), neuronal damage (MESH:D009410), chronic diseases (MESH:D002908), VCI (MESH:D003072)
- **Chemicals:** Glucoside (MESH:D005960), sulfate (MESH:D013431), sugar (MESH:D000073893), metal (MESH:D008670), glucuronide (MESH:D020719), quercetin glycosides (MESH:D012431), hesperidin (MESH:D006569), Quercetin (MESH:D011794), Polysaccharides (MESH:D011134), catechin (MESH:D002392), catechol (MESH:C034221), kaempferol (MESH:C006552), water (MESH:D014867), phospholipids (MESH:D010743), hyaluronic acid (MESH:D006820), flavonol (MESH:C041477), aglycone (MESH:C458179), sodium (MESH:D012964), quercetin-3-O-glucuronide (MESH:C443401), 3-O-glucoside (-), naringin (MESH:C005274), isoquercitrin (MESH:C016527), polyphenol (MESH:D059808), ATP (MESH:D000255), Evans blue (MESH:D005070), ROS (MESH:D017382), Calcium (MESH:D002118), flavonoid (MESH:D005419), hydrogen (MESH:D006859), luteolin (MESH:D047311), NAD+ (MESH:D009243), dopamine (MESH:D004298)
- **Species:** Malus domestica (apple, species) [taxon 3750], Arachis hypogaea (goober, species) [taxon 3818], Lyssavirus rabies (species) [taxon 11292], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Allium cepa (onion, species) [taxon 4679]
- **Cell lines:** SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956729/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12956729/full.md

## References

141 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956729/full.md

---
Source: https://tomesphere.com/paper/PMC12956729